Moxylin isn't suitable for some people. To make sure Moxylin is safe for you, tell your doctor if you:
The half-life of Moxylin is 61.3 minutes. Approximately 60% of an orally administered dose of Moxylin is excreted in the urine within 6 to 8 hours. Detectable serum levels are observed up to 8 hours after an orally administered dose of Moxylin. Since most of the Moxylin is excreted unchanged in the urine, its excretion can be delayed by concurrent administration of probenecid .
The concurrent administration of allopurinol and Moxylin increases the incidence of rashes in patients receiving both drugs as compared to patients receiving Moxylin alone. It is not known whether this potentiation of Moxylin rashes is due to allopurinol or the hyperuricemia present in these patients.
What other information should I know?
Keep all appointments with your doctor and the laboratory. Your doctor may order certain lab tests to check your body's response to Moxylin.
If you are diabetic, use Clinistix or TesTape (not Clinitest) to test your urine for sugar while taking this medication.
Do not let anyone else take your medication. Your prescription is probably not refillable. If you still have symptoms of infection after you finish the Moxylin, call your doctor.
It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.
Before taking Moxylin,
- tell your doctor and pharmacist if you are allergic to Moxylin; penicillin antibiotics; cephalosporin antibiotics such as cefaclor, cefadroxil, cefazolin (Ancef, Kefzol), cefepime (Maxipime), cefixime (Suprax), cefotaxime (Claforan), cefotetan, cefoxitin (Mefoxin), cefpodoxime, cefprozil, ceftaroline (Teflaro), ceftazidime (Fortaz, Tazicef, in Avycaz), ceftibuten, ceftriaxone, cefuroxime (Ceftin, Zinacef), and cephalexin (Keflex); any other medications; or any of the ingredients in Moxylin capsules, tablets, or suspension. Ask your pharmacist for a list of the ingredients.
- tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: allopurinol (Lopurin, Zyloprim), other antibiotics, anticoagulants ('blood thinners') such as warfarin (Coumadin, Jantoven), oral contraceptives, and probenecid (Probalan, in Col-Probenecid). Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
- tell your doctor if you have mononucleosis (a virus; also called 'mono') and if you have or have ever had kidney disease, allergies, asthma, hay fever, or hives.
- tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. If you become pregnant while taking Moxylin, call your doctor.
- if you have phenylketonuria (PKU, an inherited condition in which a special diet must be followed to prevent mental retardation), you should know that some Moxylin chewable tablets are sweetened with aspartame that forms phenylalanine.
Why is this medication prescribed?
Moxylin is used to treat certain infections caused by bacteria, such as pneumonia; bronchitis (infection of the airway tubes leading to the lungs); and infections of the ears, nose, throat, urinary tract, and skin. It is also used in combination with other medications to eliminate H. pylori, a bacteria that causes ulcers. Moxylin is in a class of medications called penicillin-like antibiotics. It works by stopping the growth of bacteria.
Antibiotics such as Moxylin will not work for colds, flu, and other viral infections. Taking antibiotics when they are not needed increases your risk of getting an infection later that resists antibiotic treatment.
What if I take too much?
Accidentally taking an extra dose of Moxylin is unlikely to harm you or your child.
Speak to your pharmacist or doctor if you're worried or you take more than 1 extra dose.
Like all medicines, Moxylin can cause side effects, although not everyone gets them.
125 mg/5 mL, 200 mg/5 mL, 250 mg/5 mL, 400 mg/5 mL. Each 5 mL of reconstituted strawberry-flavored suspension contains 125 mg Moxylin as the trihydrate. Each 5 mL of reconstituted bubble-gumflavored suspension contains 200 mg, 250 mg or 400 mg Moxylin as the trihydrate.
Moxylin may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:
- changes in taste
Why it’s used
Moxylin is an antibiotic. It’s used to treat infections caused by a certain type of bacteria.
Moxylin may be used as part of a combination therapy. This means you may need to take it with other medications.
More common side effects
The more common side effects of Moxylin oral tablet can include:
If these side effects are mild, they may go away within a few days or a couple of weeks. If they’re more severe or don’t go away, talk to your doctor or pharmacist.
An overdose of Moxylin should be reported to your regional emergency situation center, so make certain you constantly take the appropriate amount. Taking even more of Moxylin could generate the complying with symptoms: serious skin breakout, complication, habits modifications, and seizure. Your doctor requires to understand if you are taking other medications, especially antibiotics, probenecid, sulfa medicines, or methotrexate. If you obtain such adverse effects as vomiting, queasiness, frustration, thrush, tummy discomfort, or vaginal itchiness, there is no have to fret - these negative side effects will most likely go away on their very own.
H. pylori Eradication To Reduce The Risk Of Duodenal Ulcer Recurrence
Randomized, double-blind clinical studies performed in the United States in patients with H. pylori and duodenal ulcer disease (defined as an active ulcer or history of an ulcer within 1 year) evaluated the efficacy of lansoprazole in combination with Moxylin capsules and clarithromycin tablets as triple 14-day therapy, or in combination with Moxylin capsules as dual 14-day therapy, for the eradication of H. pylori. Based on the results of these studies, the safety and efficacy of 2 different eradication regimens were established: Triple therapy: Moxylin 1 gram twice daily/clarithromycin 500 mg twice daily/lansoprazole 30 mg twice daily (see Table 6). Dual therapy: Moxylin 1 gram three times daily/lansoprazole 30 mg three times daily (see Table 7. All treatments were for 14 days. H. pylori eradication was defined as 2 negative tests (culture and histology) at 4 to 6 weeks following the end of treatment. Triple therapy was shown to be more effective than all possible dual therapy combinations. Dual therapy was shown to be more effective than both monotherapies. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence.
Table 6: H. pylori Eradication Rates When Moxylin is Administered as Part of a Triple Therapy Regimen
Table 7: H. pylori Eradication Rates When Moxylin is Administered as Part of a Dual Therapy Regimen
1. Swanson-Biearman B, Dean BS, Lopez G, Krenzelok EP. The effects of penicillin and cephalosporin ingestions in children less than six years of age. Vet Hum Toxicol. 1988; 30: 66-67.
2. Clinical and Laboratory Standards Institute (CLSI). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard – Tenth Edition. CLSI document M07-A10, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2015.
3. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Disk Diffusion Susceptibility Tests; Approved Standard – Twelfth Edition. CLSI document M02-A12, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2015.
4. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; Twenty-fifth Informational Supplement, CLSI document M100-S25. CLSI document M100-S25, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2015.
How should Moxylin be given?
Give this medication exactly as directed by your veterinarian. Moxylin can be given with or without food. Give all of the Moxylin even if your pet appears to be better. Symptoms may improve before the infection is completely treated.
Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin therapy including Moxylin. Although anaphylaxis is more frequent following parenteral therapy, it has occurred in patients on oral penicillins. These reactions are more likely to occur in individuals with a history of penicillin hypersensitivity and/or a history of sensitivity to multiple allergens. There have been reports of individuals with a history of penicillin hypersensitivity who have experienced severe reactions when treated with cephalosporins. Before initiating therapy with AMOXIL, careful inquiry should be made regarding previous hypersensitivity reactions to penicillins, cephalosporins, or other allergens.
Formulations of AMOXIL contain Moxylin, a semisynthetic antibiotic, an analog of ampicillin, with a broad spectrum of bactericidal activity against many Gram-positive and Gram-negative microorganisms. Chemically, it is (2S,5,R,6,R)-6--3,3-dimethyl-7-oxo-4-thia-1-azabicycloheptane-2-carboxylic acid trihydrate. It may be represented structurally as:
The Moxylin molecular formula is C16H19N3O5S•3H2O, and the molecular weight is 419.45.
Capsules: Each capsule of AMOXIL, with royal blue opaque cap and pink opaque body, contains 250 mg or 500 mg Moxylin as the trihydrate. The cap and body of the 250-mg capsule are imprinted with the product name AMOXIL and 250; the cap and body of the 500-mg capsule are imprinted with AMOXIL and 500. Inactive ingredients: D&C Red No. 28, FD&C Blue No. 1, FD&C Red No. 40, gelatin, magnesium stearate, and titanium dioxide.
Tablets: Each tablet contains 500 mg or 875 mg Moxylin as the trihydrate. Each film-coated, capsule-shaped, pink tablet is debossed with AMOXIL centered over 500 or 875, respectively. The 875-mg tablet is scored on the reverse side. Inactive ingredients: Colloidal silicon dioxide, crospovidone, FD&C Red No. 30 aluminum lake, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, sodium starch glycolate, and titanium dioxide.
Powder for Oral Suspension: Each 5 mL of reconstituted suspension contains 125 mg, 200 mg, 250 mg or 400 mg Moxylin as the trihydrate. Each 5 mL of the 125-mg reconstituted suspension contains 0.11 mEq (2.51 mg) of sodium. Each 5 mL of the 200-mg reconstituted suspension contains 0.15 mEq (3.39 mg) of sodium. Each 5 mL of the 250-mg reconstituted suspension contains 0.15 mEq (3.36 mg) of sodium; each 5 mL of the 400-mg reconstituted suspension contains 0.19 mEq (4.33 mg) of sodium. Inactive ingredients: FD&C Red No. 3, flavorings, silica gel, sodium benzoate, sodium citrate, sucrose, and xanthan gum.
Moxylin is stable in the presence of gastric acid and is rapidly absorbed after oral administration. The effect of food on the absorption of Moxylin from the tablets and suspension of AMOXIL has been partially investigated; 400-mg and 875-mg formulations have been studied only when administered at the start of a light meal.
Orally administered doses of 250-mg and 500-mg Moxylin capsules result in average peak blood levels 1 to 2 hours after administration in the range of 3.5 mcg/mL to 5.0 mcg/mL and 5.5 mcg/mL to 7.5 mcg/mL, respectively.
Mean Moxylin pharmacokinetic parameters from an open, two-part, single-dose crossover bioequivalence study in 27 adults comparing 875 mg of AMOXIL with 875 mg of AUGMENTIN® (Moxylin/clavulanate potassium) showed that the 875-mg tablet of AMOXIL produces an AUC0-∞ of 35.4 ± 8.1 mcg•hr/mL and a Cmax of 13.8 ± 4.1 mcg/mL. Dosing was at the start of a light meal following an overnight fast.
Orally administered doses of Moxylin suspension, 125 mg/5 mL and 250 mg/5 mL, result in average peak blood levels 1 to 2 hours after administration in the range of 1.5 mcg/mL to 3.0 mcg/mL and 3.5 mcg/mL to 5.0 mcg/mL, respectively.
Oral administration of single doses of 400-mg chewable tablets and 400 mg/5 mL suspension of AMOXIL to 24 adult volunteers yielded comparable pharmacokinetic data:
Table 3: Mean Pharmacokinetic Parameters of Moxylin (400 mg chewable tablets and 400 mg/5 mL suspension) in Healthy Adults